Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -13.06, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 128.09M shares, increasing 5.38% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 30.83K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.40.